Back to results
US 8,507,195 B2Granted
MiRNAs dysregulated in triple-negative breast cancer
AssigneeThe Regents of the University of Colorado
InventorsJennifer Richer, Dawn Cochrane, Steven M. Anderson
Life of this patent
Estimating the term…
Abstract
The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.
Claims14
A method of identifying “triple-negative” breast cancer in a subject comprising:
- (a) obtaining a breast cancer tissue sample from said subject;
- and
- (b) assessing said sample for one or more miRNAs selected from the group consisting of miR-193b, miR-34a, miR-301a, miR-148a and/or miR-15b;
- wherein decreased levels of one or more of miR-193b, miR-34a, miR-301a, miR-148a and/or miR-15b in said sample, as compared to a luminal breast cancer, indicates that said subject has a “triple-negative” breast cancer.
1 more element
Dependencies are inferred from the claim text.